目的:观察含奈达铂(NDP)化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:96例ⅢB或者Ⅳ期NSCLC患者,随机分为NDP组和顺铂(DDP)组,A组:NDP 80～100mg/m2,静脉滴入,d1。B组:DDP 80～100mg/m2,静脉滴入,d1或分3d,两组均分别联合长春瑞滨、泽菲或者多西紫杉醇化疗。21d为1个周期,治疗4～6个周期。结果:A组总有效率为38.0%,鳞癌有效率为51.9%,腺癌有效率为21.7%,两者疗效比较差异有统计学意义,χ2=4.78,P<0.05。B组总的有效率为41.3%,鳞癌化疗有效率为40.9%,腺癌化疗有效率为41.7%,两者疗效比较差异无统计学意义,χ2=0.003,P>0.05。A组的胃肠道反应较B组明显减轻。骨髓抑制和肝肾功能损坏大致相同。A组中位疾病进展时间6.8个月,B组中位疾病进展时间6.7个月,两组比较差异无统计学意义,P>0.05。A组中位生存时间11.9个月,B组中位生存时间12.5个月,两组中位生存时间差异无统计学意义,P>0.05。A组1和2年生存率分别为45.0%和2.0%,而B组1和2年生存率分别42.0%和3.2%,均差异无统计学意义,P>0.05。结论:含NDP的化疗方案治疗晚期NSCLC疗效与DDP组相当,但毒副反应较轻,尤其适用于转移性鳞癌。 Objective: To observe the clinical efficacy and adverse reactions of NDP-containing chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: A total of 96 patients with stage ⅢB or Ⅳ NSCLC were randomly divided into NDP group and cisplatin (DDP) group. A group received NDP 80-100 mg / m2 intravenously and d1. Group B: DDP 80 ~ 100mg / m2, intravenous infusion, d1 or 3d, respectively, two groups were combined with vinorelbine, Zephyr or docetaxel chemotherapy. 21d for a period of 4 to 6 cycles of treatment. Results: The total effective rate in group A was 38.0%, that in squamous cell carcinoma was 51.9%, and that in adenocarcinoma was 21.7%. The difference between the two groups was statistically significant (χ2 = 4.78, P <0.05). The overall effective rate was 41.3% in group B, 40.9% in squamous cell carcinoma, and 41.7% in adenocarcinoma. There was no significant difference between the two groups (χ2 = 0.003, P> 0.05). Gastrointestinal reaction in group A was significantly reduced than that in group B. Myelosuppression and liver and kidney damage is about the same. The progression time of median disease in group A was 6.8 months and that in group B was 6.7 months. There was no significant difference between the two groups (P> 0.05). The median survival time in group A was 11.9 months, and the median survival time in group B was 12.5 months. There was no significant difference in the median survival time between the two groups (P> 0.05). The 1-year and 2-year survival rates in group A were 45.0% and 2.0%, respectively, while the 1-year and 2-year survival rates in group B were 42.0% and 3.2% respectively, with no significant difference (P> 0.05). Conclusion: The efficacy of NDP-containing chemotherapy in the treatment of advanced NSCLC is equivalent to that of DDP group, but the side effects are mild, especially for metastatic squamous cell carcinoma.